Mefoxin

Cefoxitin, the active ingredient in Mefoxin, is a second‑generation cephalosporin presented as an intravenous formulation for parenteral use. It treats a range of bacterial infections in adult patients, including respiratory, urinary, intra‑abdominal, skin and soft‑tissue, and gynecologic infections.

GNH USA supplies Mefoxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Cefoxitin is a broad‑spectrum cephalosporin used to manage bacterial infections across several organ systems.

- Respiratory tract infections: provides bacterial clearance leading to clinical improvement. - Urinary tract infections: eradicates causative pathogens and resolves symptoms. - Intra‑abdominal infections: controls polymicrobial infection after surgery or perforation. - Skin and soft‑tissue infections: eliminates susceptible Gram‑positive and Gram‑negative organisms. - Gynecologic infections: treats postoperative or endogenous pelvic infections effectively.

Cefoxitin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Rash: transient erythematous skin eruptions. - Elevated liver enzymes: transient increase in ALT/AST. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: severe intestinal inflammation. - Hemolytic anemia: destruction of red blood cells. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: worsening kidney function in susceptible patients.

Cefoxitin should be used with caution in specific clinical situations.

- Allergy assessment: verify no known hypersensitivity to cephalosporins or penicillins. - Renal function: adjust dosing in patients with impaired kidney function. - Hepatic function: monitor liver enzymes in patients with liver disease. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Concomitant antibiotics: avoid unnecessary combination therapy to reduce resistance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Cefoxitin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when co‑administered. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Diuretics: may affect electrolyte balance; monitor serum levels. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Probenecid: may increase cefoxitin plasma concentrations. - Antacids containing aluminum or magnesium: may interfere with absorption if oral forms were used. - Other beta‑lactams: assess for additive toxicity, especially in renal impairment.